

NEWS RELEASE

CORDLIFE COMPLETES ACQUISITION OF 10% EQUITY IN NYSE-LISTED CHINA CORD BLOOD CORPORATION

- ***Also completes disposal of its 10% indirect stake in China Stem Cells (South) Company Limited;***
- ***Transactions strengthen strategic alliance with China's largest cord blood banking operator;***
- ***In line with Cordlife's strategy to expand geographical reach in China.***

Singapore, 12 November 2012 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a cord blood and tissue banking service provider, announced today that it has completed the acquisition of 10% of issued shares in China Cord Blood Corporation (“CCBC”) and the disposal of its 10% indirect stake in China Stem Cells (South) Company Limited (“CSCS”). The transactions, encompassing the acquisition and the disposal, were first announced on 15 August 2012, and subsequently approved by Cordlife's shareholders on 19 October 2012 at an Extraordinary General Meeting.

Mr. Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife, was appointed to CCBC's board of directors as an independent non-executive director, with effect from the closing of the acquisition.

Mr Yee said: “The completion of this transactions and my appointment to the CCBC board further cement the strategic relationship we have with CCBC, China's largest cord blood banking operator. Cordlife will now own approximately 10% of CCBC and be able to capitalise on the tremendous growth opportunities of its businesses in China, where a fast-rising middle class keen on seeking better healthcare options for their children is driving demand for cord blood banking services. This is in line with Cordlife's strategy to expand its geographical reach in China.”

The initial public offering of Cordlife Group Limited's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd. (“Issue Manager”). The Issue Manager assumes no responsibility for the contents of this press release.

CCBC, which is listed on the New York Stock Exchange (“NYSE”), provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services in the Beijing municipality and the provinces of Guangdong and Zhejiang.

The consideration for the acquisition of approximately US\$20.8 million was partly offset by the disposal consideration of US\$16.8 million. As announced by Cordlife, the remaining acquisition consideration of approximately US\$4.0 million was funded by and disbursed out of the net proceeds raised from Cordlife’s initial public offering (“IPO”) on the Singapore Exchange Securities Trading Limited in March 2012. Such utilisation of Cordlife's IPO proceeds is in accordance with the intended use stated and percentage allocated in Cordlife’s prospectus.

“The transactions are accretive and essentially allow Cordlife to exchange its equity stake in a private company, CSCS, for ordinary shares in CCBC, which can be publicly traded on the NYSE¹, thereby potentially increasing the liquidity of Cordlife’s investment and portfolio, and further unlocking shareholder value,” Mr Yee said.

¹ *Subject to registration of such CCBC shares with the US Securities and Exchange Commission or the availability of an exemption therefore.*

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited is an award-winning and established cord blood banking service provider. Amongst the first private cord blood banks in Asia, the Group has established a dominant market leader position in Singapore*. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks.

The Group collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways.

Cordlife's business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals & clinics such as Thomson Medical, Parkway East Hospital and Raffles Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has 10% direct stake in China Cord Blood Corporation – a top operator in China providing umbilical cord blood stem cells storage services in Beijing municipality, Guangdong province and Zhejiang province, and an approximately 20% equity interest in Shandong Cord Blood Bank.

**According to the industry data in the Company's prospectus dated March 21, 2012.*

Cordlife was amongst the first in Asia to be accredited by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2011 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7**. In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category.

***Awarded to Cordlife Hong Kong.*

ABOUT CHINA CORD BLOOD CORPORATION (NYSE: CO)

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorised as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit its website at <http://www.chinacordbloodcorp.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Citigate Dewe Rogerson, i.MAGE Pte Ltd
1 Raffles Place
#26-02 One Raffles Place
SINGAPORE 048616
CONTACT : Ms Dolores Phua / Ms Chelsea Phua
DURING OFFICE HOURS : 6534-5122 (Office)
AFTER OFFICE HOURS : 9750-8237 / 9667-5837 (Handphone)
EMAIL : dolores.phua@citigatedrimage.com /
chelsea.phua@citigatedrimage.com

128/12/005/CGL

November 12, 2012